The general objective of this report is to analyze the biosimilar market in Spain and by autonomous communities from 2016 to 2022. For this purpose, a descriptive analysis of the consumption of biosimilar medicines financed and marketed in Spain from 2016 to 2022 has been carried out. 51 based on official data provided by the Ministry of Health. These data include 14 biosimilar medicines for the XNUMX active ingredients that had at least one biosimilar approved and marketed during this time period. Furthermore, the penetration of biosimilar medicines in the Spanish market has been compared with that of the Italian and Portuguese markets, countries that have official public data. Outside the objective of this study is the analysis of prices or potential savings of biosimilar medicines in the Spanish market since there are other recent studies on this topic.